A Phase 2 study of GSK4532990 in alcohol-related liver disease

Study Description

A study to investigate a new medication for alcohol-related liver disease

Study Details

Registry ID:

NCT06613698

Conditions:

Liver Diseases, Alcoholic

Phase:

Phase 2

Target Enrollment:

393 participants

Start Date:

September 27, 2024

Healthy Volunteers:

No

Study Locations (108 sites)

• GSK Investigational Site
  Glasgow StrathclydeUnited Kingdom, United Kingdom
• GSK Investigational Site
  Leeds West YorkshireUnited Kingdom, United Kingdom
• GSK Investigational Site
  SevilleSpain, Spain
• GSK Investigational Site
  ValenciaSpain, Spain
• GSK Investigational Site
  MadridSpain, Spain
• GSK Investigational Site
  MessinaItaly, Italy
• GSK Investigational Site
  BarcelonaSpain, Spain
• GSK Investigational Site
  ValladolidSpain, Spain
• GSK Investigational Site
  LeonSpain, Spain
• GSK Investigational Site
  VigoSpain, Spain
• GSK Investigational Site
  SantanderSpain, Spain
• GSK Investigational Site
  MontpellierFrance, France
• GSK Investigational Site
  AthensGreece, Greece
• GSK Investigational Site
  PadovaItaly, Italy
• GSK Investigational Site
  BolognaItaly, Italy
• GSK Investigational Site
  RomaItaly, Italy
• GSK Investigational Site
  MilanoItaly, Italy
• GSK Investigational Site
  BergamoItaly, Italy
• GSK Investigational Site
  PaduaItaly, Italy
• GSK Investigational Site
  IzmirTurkey, Turkey
• GSK Investigational Site
  AngersFrance, France
• GSK Investigational Site
  Kocaeli, İzmitTurkey (Türkiye), Turkey (Türkiye)
• GSK Investigational Site
  CréteilFrance, France
• GSK Investigational Site
  BobignyFrance, France
• GSK Investigational Site
  RouenFrance, France
• GSK Investigational Site
  IstanbulTurkey (Türkiye), Turkey (Türkiye)
• GSK Investigational Site
  PlymouthUnited Kingdom, United Kingdom
• GSK Investigational Site
  MainzGermany, Germany
• GSK Investigational Site
  LilleFrance, France
• GSK Investigational Site
  Adana, YüreğirTurkey (Türkiye), Turkey (Türkiye)
• GSK Investigational Site
  LondonUnited Kingdom, United Kingdom
• GSK Investigational Site
  BristolUnited Kingdom, United Kingdom
• GSK Investigational Site
  Bochum, North Rhine-WestphaliaGermany, Germany
• GSK Investigational Site
  CambridgeUnited Kingdom, United Kingdom
• GSK Investigational Site
  LeipzigGermany, Germany
• GSK Investigational Site
  LiverpoolUnited Kingdom, United Kingdom
• GSK Investigational Site
  KatowicePoland, Poland
• GSK Investigational Site
  MysłowicePoland, Poland
• GSK Investigational Site
  BerlinGermany, Germany
• GSK Investigational Site
  MiddlesbroughUnited Kingdom, United Kingdom
• GSK Investigational Site
  KielGermany, Germany
• GSK Investigational Site
  Diyarbakır, SurTurkey (Türkiye), Turkey (Türkiye)
• GSK Investigational Site
  EsbjergDenmark, Denmark
• GSK Investigational Site
  WarsawPoland, Poland
• GSK Investigational Site
  Odense CDenmark, Denmark
• GSK Investigational Site
  HvidovreDenmark, Denmark
• GSK Investigational Site
  StockholmSweden, Sweden
• GSK Investigational Site
  UppsalaSweden, Sweden
• GSK Investigational Site
  Buenos AiresArgentina, Argentina
• GSK Investigational Site
  RosarioArgentina, Argentina
• GSK Investigational Site
  San Miguel de TucumánArgentina, Argentina
• GSK Investigational Site
  Miami Lakes, FloridaUnited States, United States
• GSK Investigational Site
  New York, New YorkUnited States, United States
• GSK Investigational Site
  Philadelphia, PennsylvaniaUnited States, United States
• GSK Investigational Site
  Richmond, VirginiaUnited States, United States
• GSK Investigational Site
  Montreal, QuebecCanada, Canada
• GSK Investigational Site
  Terrebonne, QuebecCanada, Canada
• GSK Investigational Site
  Chapel Hill, North CarolinaUnited States, United States
• GSK Investigational Site
  Brandon, FloridaUnited States, United States
• GSK Investigational Site
  Toronto, OntarioCanada, Canada
• GSK Investigational Site
  Atlanta, GeorgiaUnited States, United States
• GSK Investigational Site
  Cleveland, OhioUnited States, United States
• GSK Investigational Site
  London, OntarioCanada, Canada
• GSK Investigational Site
  Detroit, MichiganUnited States, United States
• GSK Investigational Site
  Indianapolis, IndianaUnited States, United States
• GSK Investigational Site
  Marrero, LouisianaUnited States, United States
• GSK Investigational Site
  DFMexico, Mexico
• GSK Investigational Site
  Mexico CityMexico, Mexico
• GSK Investigational Site
  Ciudad de MexicoMexico, Mexico
• GSK Investigational Site
  Dallas, TexasUnited States, United States
• GSK Investigational Site
  Austin, TexasUnited States, United States
• GSK Investigational Site
  Georgetown, TexasUnited States, United States
• GSK Investigational Site
  Arlington, TexasUnited States, United States
• GSK Investigational Site
  San Antonio, TexasUnited States, United States
• GSK Investigational Site
  Topeka, KansasUnited States, United States
• GSK Investigational Site
  MonterreyMexico, Mexico
• GSK Investigational Site
  AcapulgoMexico, Mexico
• GSK Investigational Site
  Tucson, ArizonaUnited States, United States
• GSK Investigational Site
  Chandler, ArizonaUnited States, United States
• GSK Investigational Site
  Phoenix, ArizonaUnited States, United States
• The Royal Perth Hospital
  Perth, Western AustraliaAustralia, Australia
• Fiona Stanley Hospital
  Murdoch, Western AustraliaAustralia, Australia
• GSK Investigational Site
  Las Vegas, NevadaUnited States, United States
• GSK Investigational Site
  Los Angeles, CaliforniaUnited States, United States
• GSK Investigational Site
  Calgary, AlbertaCanada, Canada
• GSK Investigational Site
  Davis, CaliforniaUnited States, United States
• GSK Investigational Site
  AnsanKorea, Republic of, Korea, Republic of
• GSK Investigational Site
  Bucheon-siSouth Korea, South Korea
• GSK Investigational Site
  Suwon Gyeonggi-doKorea, Republic of, Korea, Republic of
• GSK Investigational Site
  New Westminster, British ColumbiaCanada, Canada
• GSK Investigational Site
  SeoulKorea, Republic of, Korea, Republic of
• GSK Investigational Site
  Vancouver, British ColumbiaCanada, Canada
• GSK Investigational Site
  DaeguSouth Korea, South Korea
• GSK Investigational Site
  KagawaJapan, Japan
• GSK Investigational Site
  EhimeJapan, Japan
• GSK Investigational Site
  OsakaJapan, Japan
• GSK Investigational Site
  NaraJapan, Japan
• GSK Investigational Site
  ShizuokaJapan, Japan
• The Royal Adelaide Hospital
  Adelaide, South AustraliaAustralia, Australia
• GSK Investigational Site
  GunmaJapan, Japan
• GSK Investigational Site
  NiigataJapan, Japan
• GSK Investigational Site
  TokyoJapan, Japan
• GSK Investigational Site
  SaitamaJapan, Japan
• GSK Investigational Site
  ChibaJapan, Japan
• GSK Investigational Site
  HokkaidoJapan, Japan
• The Royal Melbourne Hospital
  Parkville, VictoriaAustralia, Australia
• The Alfred Hospital
  Melbourne, VictoriaAustralia, Australia
• Wits Clinical Research Parktown
  Johannesburg, GautengSouth Africa, South Africa

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.org.

View full study details and check eligibility →